{"ticker": {"uuid": "ab5da8d0-97dd-4209-8510-70ad3dac23d5", "symbol": "LEGN", "name": "Legend Biotech\u00a0Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed", "summary": "LEGEND BIOTECH CORPORATION (LEGN) disclosed $90,000 in lobbying expenses for Q2 2026, focusing on educating Congress about biotechnology's role in healthcare. Insider trading data shows two sales by the CEO, totaling $169,404, while hedge funds exhibit mixed activity with signifi", "url": "https://www.quiverquant.com/news/Lobbying+Update%3A+%2490%2C000+of+LEGEND+BIOTECH+CORPORATION+lobbying+was+just+disclosed", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T23:13:00", "published_display": "15 Jul 2026 23:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI sales", "summary": "Legend Biotech (NASDAQ: LEGN) reported preliminary net trade sales of approximately $657 million for CARVYKTI\u00ae for the quarter ended June 30, 2026, based on data provided by Janssen. This figure has not been independently verified or audited by Legend Biotech's accountants and is", "url": "https://www.stocktitan.net/sec-filings/LEGN/6-k-legend-biotech-corp-current-report-foreign-issuer-31818306fd43.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:13:30", "published_display": "15 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com", "summary": "JPMorgan has resumed coverage of Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target of $35.00 for December 2027. The firm acknowledges the strong launch of Legend Biotech's Carvykti but expresses concerns about competitive threats and the unproven potent", "url": "https://ng.investing.com/news/stock-market-news/jpmorgan-resumes-legend-biotech-stock-coverage-with-neutral-rating-93CH-2596024", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T12:10:51", "published_display": "13 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutra", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOSVBVT200UVJiZDdHR29BSVQ5QVJ5VnJheXhyS1FZUVdJcFFPRmd3RGdGU05ESGJOc29KZEM1QkpXOEQyNFpGRWdLUVNDQ2xFeHRFV2xjOEFwV3FVcENlV2wxWWUzeFQybV9mdHlidUlDUmF3SFh1eHZpXzlPVFRsVnhDVndaRzFOM1A4M2dWZ181REFYRzRIN1FJREVkdEs4OW5yU3VtQzE3aDlnOWxB?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T10:50:16+00:00", "published_display": "13 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN Reinstated by JP Morgan -- Rating Set to Neutral", "summary": "JP Morgan has reinstated Legend Biotech (LEGN) with a Neutral rating and a price target of $35.00, reflecting a cautious outlook despite the stock being significantly undervalued according to GuruFocus's GF Value\u2122. While LEGN shows strong growth potential and momentum, its high f", "url": "https://www.gurufocus.com/news/8955167/legn-reinstated-by-jp-morgan-rating-set-to-neutral", "source_name": "GuruFocus", "published_at": "2026-07-13T11:41:49", "published_display": "13 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutral Outlook", "summary": "JPMorgan has initiated coverage of Legend Biotech (LEGN) with a Neutral rating and a $35 price target, citing a strong launch for its CAR T-cell therapy Carvykti but expressing caution regarding competitive pressures. The company, with a market cap of $5.24 billion and a GF Score", "url": "https://www.gurufocus.com/news/8954992/jpmorgan-initiates-coverage-of-legend-biotech-legn-with-neutral-outlook", "source_name": "GuruFocus", "published_at": "2026-07-13T10:41:49", "published_display": "13 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 111% Potential Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPWHcwd3RtMFRGM3hBNzJlSElsM0hQWHFfX3BYb1ZkTmpKcnZaZUREaHYzUTVrSHc0OUhiRlFVNHRKVjQtNEMzMTBwUFVRRFpVQk5lX2QwLWxaMnpzLWNRcmpfQWhGWV9kYVVMZ0tjYzlwT0NBaGhWems5YTUtY0FOZ2pQYjhVbkF4Ti1YQk15WC1TcHN1cjRlUHZmaG5JM1lMNTBIUmhZYzljT04xX1djRnFwWXBrcnRIWmplQ1ZrSV94ZERwZXdUN2YzN3BOMUptVVh4b09mNnliY2NKc08weEJ5YVUxZHc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:23:55+00:00", "published_display": "13 Jul 2026 09:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026", "summary": "As of June 30, 2026, Legend Biotech (LEGN) had a short interest of 13.11 million shares, representing 7.06% of the public float. This was a 0.96% increase from the previous report, with a short interest ratio of 4.2 days to cover. The article provides a detailed historical overvi", "url": "https://www.marketbeat.com/stocks/NASDAQ/LEGN/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T07:10:51", "published_display": "10 Jul 2026 07:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating", "summary": "RBC Capital has revised its price target for Legend Biotech (NASDAQ: LEGN) to $63, down from $64, while reaffirming its \"Outperform\" rating on the stock. This adjustment comes amidst recent news regarding the company's financial activities and clinical trial data. Legend Biotech ", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-legend-biotech-price-target-to-63-from-64-maintains-outperform-rating-ce7f5ed8d981f620", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T12:11:26", "published_display": "07 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corp highlights cell therapy pipeline as shares trade on Nasdaq", "summary": "Legend Biotech Corp is advancing its cell therapy pipeline, focusing on oncology and immunology treatments, as its shares trade on Nasdaq. The company specializes in autologous cell therapy platforms and is recognized for its investigational therapies in hematologic malignancies ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/legend-biotech-corp-highlights-cell-therapy-pipeline-as-shares-trade-on/69682949", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T22:13:10", "published_display": "03 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares", "summary": "Legend Biotech Corp's CEO and director, Ying Huang, reported a charitable gift of 3,382 Ordinary Shares to a charitable organization. This transaction, filed as a Form 4, involved no cash consideration and leaves Huang with a direct ownership of 238,490 Ordinary Shares. The compa", "url": "https://www.stocktitan.net/sec-filings/LEGN/form-4-legend-biotech-corp-insider-trading-activity-e0c9e191f7ac.html", "source_name": "Stock Titan", "published_at": "2026-07-03T18:10:18", "published_display": "03 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) director sells 6,000 shares at $14.80 each in open-market trade", "summary": "Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction at $14.80 per share, or $29.60 per American Depositary Share (ADS). After the sale, Mr. John directly holds 48,604 Ordinary Shares, indicating a continued significant equity s", "url": "https://www.stocktitan.net/sec-filings/LEGN/form-4-legend-biotech-corp-insider-trading-activity-d2ab9a520a61.html", "source_name": "Stock Titan", "published_at": "2026-07-03T18:10:18", "published_display": "03 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Patrick Casey Sells 6,000 Shares of Legend B", "summary": "Patrick Casey, a Director at Legend Biotech Corp (LEGN), sold 6,000 shares of the company on June 30, 2026, reducing his holdings to 48,604 shares. This transaction follows a period of no insider buys and three insider sells over the past year for Legend Biotech. The stock is cur", "url": "https://www.gurufocus.com/news/8943775/insider-sell-alert-patrick-casey-sells-6000-shares-of-legend-biotech-corp-legn", "source_name": "GuruFocus", "published_at": "2026-07-02T23:10:26", "published_display": "02 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN - Legend Biotech Corp ADR Earnings", "summary": "This article provides detailed financial data and performance metrics for Legend Biotech Corp ADR (LEGN). It includes key financial figures like market cap, income, sales, EPS, and various ratios, alongside stock performance over different periods. The data also covers ownership ", "url": "https://finviz.com/stock?t=LEGN&ta=1&p=w&ty=ea&b=2", "source_name": "Finviz", "published_at": "2026-07-02T16:39:24", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation Stock 12\u2011Month Price Target Cut to $55.21, Implies 85% Upside", "summary": "Legend Biotech Corporation's average 12-month stock price target has been lowered from $56.13 to $55.21 by 14 analysts, with forecasts ranging from $27 to $86 per share. This new target implies an 85% potential upside based on the July 1 closing price. Despite the target cut, the", "url": "https://www.tradingview.com/news/tradingview:6c4df68c2f6e1:0-legend-biotech-corporation-stock-12-month-price-target-cut-to-55-21-implies-85-upside/", "source_name": "TradingView", "published_at": "2026-07-02T16:10:26", "published_display": "02 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN - Legend Biotech Corp ADR Options", "summary": "This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The dat", "url": "https://finviz.com/stock?t=LEGN&p=d&ty=oc&b=2&ov=list_strike&s=2.5", "source_name": "Finviz", "published_at": "2026-07-02T15:40:38", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Legend Biotech Corp For: 30 June By Investing.com", "summary": "This article reports on the filing of Form 144 by Legend Biotech Corp for the period ending June 30. It provides financial market data including indices, commodities, bonds, and shares, along with a list of trending stocks and recent market movers. The article is a brief announce", "url": "https://ng.investing.com/news/stock-market-news/form-144-legend-biotech-corp-for-30-june-93CH-2580509", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T15:12:37", "published_display": "01 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Proposed ADS Sale (NASDAQ: LEGN)", "summary": "A Form 144 filing indicates a proposed sale of 3,000 American Depositary Shares (ADS) of Legend Biotech Corp (NASDAQ: LEGN) through Fidelity Brokerage Services LLC, valued at $88,800. The filing also details multiple past restricted stock vesting events totaling 3,000 ADS between", "url": "https://www.stocktitan.net/sec-filings/LEGN/144-legend-biotech-corp-sec-filing-0312b4d9df8b.html", "source_name": "Stock Titan", "published_at": "2026-06-30T14:38:55", "published_display": "30 Jun 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Legend Biotech Corp For: 29 June By Investing.com", "summary": "This article announces the filing of Form 4 for Legend Biotech Corp for June 29, as reported by Investing.com. It is a brief administrative notice primarily serving to disseminate this financial filing information. The content primarily consists of market data, trending stocks, a", "url": "https://za.investing.com/news/stock-market-news/form-4-legend-biotechcorp-for-29-june-93CH-4348922", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T03:10:12", "published_display": "30 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU tax", "summary": "Legend Biotech Corp's CEO, Ying Huang, reported the disposition of 5,566 ordinary shares on June 25, 2026, at a weighted average price of $14.78 per share. This transaction was non-discretionary and solely to cover withholding tax obligations upon the vesting of restricted share ", "url": "https://www.stocktitan.net/sec-filings/LEGN/form-4-legend-biotech-corp-insider-trading-activity-e40f3d8780e6.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:10:11", "published_display": "30 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "This article displays the \"Price to sales forward\" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It provides market data and financial information for the company, accessible through the TradingView platform. The page shows that the market was closed at the", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:39:15", "published_display": "27 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN)", "summary": "This page provides an overview of Legend Biotech Corporation's financial actuals and estimates, including reported data and analyst projections for income statements, balance sheets, cash flow, and valuation metrics. Users can compare actual results with average, high, and low es", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:07", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "This article displays the \"Enterprise value to EBIT forward\" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It indicates that the market was closed with no trades at the time of the data capture. The content is primarily a screenshot or data display from the", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:11:42", "published_display": "26 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN (NASDAQ) notice: Director/entity proposes sale of 2,783 ADS", "summary": "Legend Biotech Corp (LEGN) has filed a Form 144 proposing the sale of 2,783 American Depositary Shares (ADS) linked to a Restricted Stock Vesting event on June 22, 2026. The filing indicates a value of $79,016.88 and mentions execution through Fidelity Brokerage Services LLC. It ", "url": "https://www.stocktitan.net/sec-filings/LEGN/144-legend-biotech-corp-sec-filing-49647a84329d.html", "source_name": "Stock Titan", "published_at": "2026-06-26T19:11:42", "published_display": "26 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Did the Recent CARVYKTI Data Reveal About Its Potential", "summary": "Legend Biotech's CARVYKTI demonstrates strong efficacy and safety for multiple myeloma, with recent data supporting its use earlier in treatment. The company reported a significant surge in Q1 2026 sales, driven by global expansion and improved manufacturing efficiency, positioni", "url": "https://www.kavout.com/market-lens/what-did-the-recent-carvykti-data-reveal-about-its-potential", "source_name": "Kavout | AI", "published_at": "2026-06-26T09:10:41", "published_display": "26 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "This article from TradingView is a placeholder or an incomplete page focusing on the \"Enterprise value to revenue forward\" metric for Legend Biotech Corporation (NASDAQ:LEGN). It displays basic company information and navigation links for financial data, news, and community secti", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:41", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "The article provides financial data for Legend Biotech Corporation (NASDAQ: LEGN), specifically focusing on its Price to Book Forward metric. It displays the current value, change, and percentage change for this financial indicator. The content appears to be a snapshot from a fin", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:09:48", "published_display": "25 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress", "summary": "UBS has raised its price target for Legend Biotech Corporation (LEGN) to $49, reiterating a Buy rating, due to promising early clinical findings for its LB5006 program. Additionally, the company reported positive initial clinical proof-of-concept results for LB2501, an investigat", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-corporation-legn-price-124048482.html", "source_name": "Market source", "published_at": "2026-06-25T13:09:47", "published_display": "25 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firm Advises Underwriters on Legend Biotech\u2019s Public Offering", "summary": "Wilson Sonsini Goodrich & Rosati advised the underwriters in Legend Biotech Corporation's recent underwritten public offering. Legend Biotech priced 7,700,000 American Depositary Shares at $29.35 per ADS, raising approximately $226 million before deductions. The underwriters also", "url": "https://www.wsgr.com/en/insights/firm-advises-underwriters-on-legend-biotechs-public-offering.html", "source_name": "Wilson Sonsini", "published_at": "2026-06-24T19:40:03", "published_display": "24 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Healthcare Stocks to Buy According to Wall Street Analysts", "summary": "This article identifies Legend Biotech Corporation (NASDAQ: LEGN) as one of the best healthcare stocks to buy according to Wall Street analysts, citing a price target increase by UBS and promising clinical trial results. The company's LB5006 program showed therapeutic activity an", "url": "https://www.insidermonkey.com/blog/5-best-healthcare-stocks-to-buy-according-to-wall-street-analysts-1788076/4", "source_name": "Insider Monkey", "published_at": "2026-06-24T18:40:03", "published_display": "24 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Apogee, 3 More Biotech Buyout Targets Wall Street Can\u2019t Stop Watching", "summary": "Following AbbVie's acquisition of Apogee Therapeutics, biotech M&A is seeing renewed interest. This article identifies three biotech companies as potential buyout targets for Wall Street: Revolution Medicines (RVMD), Structure Therapeutics (GPCR), and Legend Biotech (LEGN). Each ", "url": "https://247wallst.com/investing/2026/06/24/after-apogee-3-more-biotech-buyout-targets-wall-street-cant-stop-watching/", "source_name": "24/7 Wall St.", "published_at": "2026-06-24T11:55:03", "published_display": "24 Jun 2026 11:55", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Legend Biotech (LEGN) Is Down 17.3% After $226 Million Follow-On Offering Post LB2501 Data - And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Reports a Complete Response in Five of Six Patients at Its Highest Dose", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-legn-reports-complete-141426609.html", "source_name": "Insider Monkey", "published_at": "2026-06-22T14:14:26+00:00", "published_display": "22 Jun 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (NASDAQ: LEGN) prices $226M ADS sale to raise cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPYkdpOEZFVU1kdlN0NlFQZzRnV0NlT3FtNWFJSGhFck9XMmdFZzlxNUFWWHpfUVZLR0Z4TG5aZUVHcUlzejNRX1V2TlJTR2thSEVZUG5TZGdWOGxGeV82bnNWbDJZRE9BTnlSUzVRejBUZ3MtckxWLThqd0lRQlJoWld0UERSWnhNRUhhN0Q2MjFacFJ6dGhXUGFONDdaOWdpenYzWnBnUXMxYkxsM1ExZzZkSUdhZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Prices $226 Million ADS Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-prices-226-million-075949443.html", "source_name": "MT Newswires", "published_at": "2026-06-18T07:59:49+00:00", "published_display": "18 Jun 2026 07:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation Announces Pricing of Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-corporation-announces-pricing-012100514.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T01:21:00+00:00", "published_display": "18 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Starts $225 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-starts-225-million-210010263.html", "source_name": "MT Newswires", "published_at": "2026-06-17T21:00:10+00:00", "published_display": "17 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation Announces Proposed Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/legend-biotech-corporation-announces-proposed-202900189.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T20:29:00+00:00", "published_display": "17 Jun 2026 20:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech seeks $225M in stock sale as markets stay open", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOMy1wdTl6VnVPYlJBdGJYejBGZlBfeFdDZEUxSEZKN2ZDYXpjUjFnQ1FjMkJ0V1F4UWp2NjlTbTVRcnBnUXFMeklmcEwxX3ZqbW9pdUZxSlZaWEQ0S292SmZ4VUlOOWo0TkhOV3MtZl9EMDVUaUYyV2VSMkhucTFjejk5ZGd4LWJxeGR1RGtLQmZONEo4NFBFbDlaVTN5djdadjNNZXlEcVV6SFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech sets $29.35 share price for $226M offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNQUZmNG5kZnltelU4dGtDeGdYT3BXenRiZTFva1dNREpaV3ZicjRpbFZRdWlfVkhVYWxRZ0lOTDNLajVHeVI0ckVHdEdSMzYycVJvQjBkemc3d3pHb0lyZmRDODRZQXlnX1JxQkRBb0NHRmZ2OFJ3NWstcEZfQy11bmFMYmItbzMxZFJEWE0yOFgzRFJ2em5jS3lfMlVIZGtXUUJKRVFkbFZTbWRNVmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech stock falls on $225M share offering plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONC1HM0tvaE85OU9rQThHejFpaUNZOXlraVY2SUNHakd0cnAzdDhidWdRLS15UjVXdm9wbGdaNnoyWHRSZVR0SXY2R3QxQnRhNFZ0b3J4eHk1M0dXY21MQUdZaGVQa3ctS3RNV1VDRVlLeUdPTVVBWGxEZU9zcDdKejc4ZHJoOHd0d2txUDZKMVNqV2Z1SjNwZVZDTzFnelJsNzFNbDlrR05aUlk5bloySGVvVFB6bUk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Reports Promising Data for LB2501 in B-cel", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQQU9wY1pXdl9yQl9hRlBRSW1MdmZzRGRJbVVQVEtLaVFRYjhRdTcyY3NUUTlUbkxrOFVZbUJ0dFhxRm02VTlIZUlUZTBHOFRXV2JVMEtpdjJwYno2NnZEZ3RqQU5BQzdRekVnU19YbHhzMURvTzQwUlE4SlctdTFzUkdScFA0T0NBbUxPYWdSRXoyODhndGY4elZ6MDVpWUx6ZVEyQ1JJeGFvTGNUNW1xWEk0Wmx6dmQyMVQ3MlpZZmdxZ3NmN1JPY182SzcyNkZqWWhCVE5LU1hab2xfS19nOVI0TUQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Single-dose lymphoma CAR-T from Legend Biotech hits 100% response at top dose", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQQkZXQ0V6NXM3OVZhcGFqNWY5bF9qcVF3R2NyZzZNUXA0Q3NIenV4UWZJR1JUejc0bXZJdjJUaEdsekhoM1ZNQnlBaU9aNExkdEZnZE5RaGRXUFhXVWtqZFNSeEtjUlBqVXVIOC1aQkNvNG5ERXJ2clcteDBWdW4tVnRtX2xCS2RWeEZLc0lkWWFyTjNXWERnN1E0RVFyUXlFUDltZGJwSEcwTXpwWEJFYU9FOHcyRlJlUFppbg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Stock (LEGN) Opinions on In Vivo CAR-T Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQMUQ0TFdzVjdVTTBkR3VxNkFVTXp4VUJqampVRG1HQ05RemVfQ1RZTnktMGtqUzZmTFpickVvQksyNFFINWRUVl93LTdEd0JwcDJfWjlZX2E3V0phalJrWmQ4cmJ2X1ZkUGtkUTV2Z2tRZDd6OG54Qmh5aDk4VUJNeFpzek5FSERRTU42Q2JyUHA1Z3JXUDItcnpUZ0FGNlk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNbkNpTG5ua09CYm0zY2Z6OXYwSzRBVDdyZGM4SW1GUTFaWmFCbzlGRUZ3ZUcyeFpmRUlJM1VRMC04S2FQcEdjX2JQaV9JeDVHMXd5ZVhPX19VU1dyWHBDMHpCcEZQTUV0LWhCZXNSNXo5M29OOU02Sm13NE1YLWlWUEhwTk1qY2hISnVwc2V4d2NMc01acVFSUVFFVjZHdw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A China Tech Fund Opens a Biotech Position \u2014 Here's What That Actually Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNeVZBck5mY05IRzNMZFF4aEM0N0U2bkFZRExRT1gweG9YRWpyekNpaEtJS3VydVk1allOUzNWYmMtRE51SkFiTldVSnlXWEs2bVR2OWZHZVpKVmlYakZXTTJNUTNTV0hJNmxCOHppUTFJdXVkWjJocnoyaEh4QXhabVllS0hvWEVvb1lUQllXLVBodjRmbTE5d2s2SGpVUG45TmVmLTA5d3dySmdKYnJybFNqaWhGNFdwcVllRXRKV2w5X2FK?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Legend Biotech (LEGN) Valuation After Strong Q1 2026 CARVYKTI Growth And Narrowing Losses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWC02OFFwV3pvVkl3V2thZ0tyVVEyRVhQSzJWdWpLSGtPc2VMVG5YWVFORjJWS0pyNkJlOTl4S1c2VDMxd0VwYXJ3LUR3aWNmSkMyaWZTX3p2VEtQYXhmMnRUSHZ4SFJTM0k3Yk5VWVYtZnZsck1pNC1rV1RjUk1BbDhfdkhKdTNwMGNVQ0Nxd19UdV83SDk1clRsYVdjczhCTHBZYkFQYUU?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Q1 Loss Persists And Tests Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Six cell therapy experts will advise Legend on its next medicines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdGkwZGRVVHJsLWxFdjBZejJ6R0pfMWdxSUdpRHpwMGc1MGtBTE1zdEg3aDVPZkFWLTVCS1ZCTTZLZDlGS2RUajBTWE5wVGRuU1lKcC1mNVQwZDNGSE5mcS12QTJmUHFqQ1BQTDFsX3hWMDktZGFrQlNwRGQ1QWZuVkFPY1dmcjdOcFFSUFg2cDJYOHg1Y0s5c2lSMlVTbDlFMlVKWDZnT0t0ZDhhUk9hTUhBX2x4TW9K?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Legend Biotech (LEGN) One of the Overlooked Growth Stocks to Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNN0ZpWFJvZEFSZkFVUEZFb0xod1lwTkpueURHNkpaTEdEWktpRmVsU1AyUmlWYmttd1piRURxZHhySkdsREpmV21mbF83Y0thUXJkUGFmV1lNdVk2dGR4NThOU1pDaUx5X2gtYk1wRmZxTDFxZHRtLVhDNWRwdlpqdnhMaWpGckdJUzBGR0pYeThPX3luSDRTb0J2d09FaHRG?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Legend Biotech (LEGN) Story Is Shifting As Analyst Expectations Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNdEVPYkNpZk5ITEhMSWk1OHVwVjNsdkdreEhlOHVSRmFLZ01ickFzSGJmcTBUc3REMGJ4VENmRkpWQTVBc1F2bWhOUXZjZTYtT3VWRVFqSTJzTjh4V0ptNjRZdFlRbzNybWJJTnZZdFdLQU1UeUhxdkRHX2F1TXJBRkkwVWMxRHNGNklPQjBvOTVsMHBqQjMxa0lUeW0xYXk1?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Legend Biotech (LEGN) Pricing Reflect Its Value After Recent Share Price Rebound?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed", "summary": "LEGEND BIOTECH CORPORATION (LEGN) disclosed $90,000 in lobbying expenses for Q2 2026, focusing on educating Congress about biotechnology's role in healthcare. Insider trading data shows two sales by the CEO, totaling $169,404, while hedge funds exhibit mixed activity with signifi", "url": "https://www.quiverquant.com/news/Lobbying+Update%3A+%2490%2C000+of+LEGEND+BIOTECH+CORPORATION+lobbying+was+just+disclosed", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T23:13:00", "published_display": "15 Jul 2026 23:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI sales", "summary": "Legend Biotech (NASDAQ: LEGN) reported preliminary net trade sales of approximately $657 million for CARVYKTI\u00ae for the quarter ended June 30, 2026, based on data provided by Janssen. This figure has not been independently verified or audited by Legend Biotech's accountants and is", "url": "https://www.stocktitan.net/sec-filings/LEGN/6-k-legend-biotech-corp-current-report-foreign-issuer-31818306fd43.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:13:30", "published_display": "15 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com", "summary": "JPMorgan has resumed coverage of Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target of $35.00 for December 2027. The firm acknowledges the strong launch of Legend Biotech's Carvykti but expresses concerns about competitive threats and the unproven potent", "url": "https://ng.investing.com/news/stock-market-news/jpmorgan-resumes-legend-biotech-stock-coverage-with-neutral-rating-93CH-2596024", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T12:10:51", "published_display": "13 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutra", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOSVBVT200UVJiZDdHR29BSVQ5QVJ5VnJheXhyS1FZUVdJcFFPRmd3RGdGU05ESGJOc29KZEM1QkpXOEQyNFpGRWdLUVNDQ2xFeHRFV2xjOEFwV3FVcENlV2wxWWUzeFQybV9mdHlidUlDUmF3SFh1eHZpXzlPVFRsVnhDVndaRzFOM1A4M2dWZ181REFYRzRIN1FJREVkdEs4OW5yU3VtQzE3aDlnOWxB?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T10:50:16+00:00", "published_display": "13 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN Reinstated by JP Morgan -- Rating Set to Neutral", "summary": "JP Morgan has reinstated Legend Biotech (LEGN) with a Neutral rating and a price target of $35.00, reflecting a cautious outlook despite the stock being significantly undervalued according to GuruFocus's GF Value\u2122. While LEGN shows strong growth potential and momentum, its high f", "url": "https://www.gurufocus.com/news/8955167/legn-reinstated-by-jp-morgan-rating-set-to-neutral", "source_name": "GuruFocus", "published_at": "2026-07-13T11:41:49", "published_display": "13 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutral Outlook", "summary": "JPMorgan has initiated coverage of Legend Biotech (LEGN) with a Neutral rating and a $35 price target, citing a strong launch for its CAR T-cell therapy Carvykti but expressing caution regarding competitive pressures. The company, with a market cap of $5.24 billion and a GF Score", "url": "https://www.gurufocus.com/news/8954992/jpmorgan-initiates-coverage-of-legend-biotech-legn-with-neutral-outlook", "source_name": "GuruFocus", "published_at": "2026-07-13T10:41:49", "published_display": "13 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 111% Potential Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPWHcwd3RtMFRGM3hBNzJlSElsM0hQWHFfX3BYb1ZkTmpKcnZaZUREaHYzUTVrSHc0OUhiRlFVNHRKVjQtNEMzMTBwUFVRRFpVQk5lX2QwLWxaMnpzLWNRcmpfQWhGWV9kYVVMZ0tjYzlwT0NBaGhWems5YTUtY0FOZ2pQYjhVbkF4Ti1YQk15WC1TcHN1cjRlUHZmaG5JM1lMNTBIUmhZYzljT04xX1djRnFwWXBrcnRIWmplQ1ZrSV94ZERwZXdUN2YzN3BOMUptVVh4b09mNnliY2NKc08weEJ5YVUxZHc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:23:55+00:00", "published_display": "13 Jul 2026 09:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026", "summary": "As of June 30, 2026, Legend Biotech (LEGN) had a short interest of 13.11 million shares, representing 7.06% of the public float. This was a 0.96% increase from the previous report, with a short interest ratio of 4.2 days to cover. The article provides a detailed historical overvi", "url": "https://www.marketbeat.com/stocks/NASDAQ/LEGN/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T07:10:51", "published_display": "10 Jul 2026 07:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating", "summary": "RBC Capital has revised its price target for Legend Biotech (NASDAQ: LEGN) to $63, down from $64, while reaffirming its \"Outperform\" rating on the stock. This adjustment comes amidst recent news regarding the company's financial activities and clinical trial data. Legend Biotech ", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-legend-biotech-price-target-to-63-from-64-maintains-outperform-rating-ce7f5ed8d981f620", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T12:11:26", "published_display": "07 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corp highlights cell therapy pipeline as shares trade on Nasdaq", "summary": "Legend Biotech Corp is advancing its cell therapy pipeline, focusing on oncology and immunology treatments, as its shares trade on Nasdaq. The company specializes in autologous cell therapy platforms and is recognized for its investigational therapies in hematologic malignancies ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/legend-biotech-corp-highlights-cell-therapy-pipeline-as-shares-trade-on/69682949", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T22:13:10", "published_display": "03 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares", "summary": "Legend Biotech Corp's CEO and director, Ying Huang, reported a charitable gift of 3,382 Ordinary Shares to a charitable organization. This transaction, filed as a Form 4, involved no cash consideration and leaves Huang with a direct ownership of 238,490 Ordinary Shares. The compa", "url": "https://www.stocktitan.net/sec-filings/LEGN/form-4-legend-biotech-corp-insider-trading-activity-e0c9e191f7ac.html", "source_name": "Stock Titan", "published_at": "2026-07-03T18:10:18", "published_display": "03 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) director sells 6,000 shares at $14.80 each in open-market trade", "summary": "Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction at $14.80 per share, or $29.60 per American Depositary Share (ADS). After the sale, Mr. John directly holds 48,604 Ordinary Shares, indicating a continued significant equity s", "url": "https://www.stocktitan.net/sec-filings/LEGN/form-4-legend-biotech-corp-insider-trading-activity-d2ab9a520a61.html", "source_name": "Stock Titan", "published_at": "2026-07-03T18:10:18", "published_display": "03 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Patrick Casey Sells 6,000 Shares of Legend B", "summary": "Patrick Casey, a Director at Legend Biotech Corp (LEGN), sold 6,000 shares of the company on June 30, 2026, reducing his holdings to 48,604 shares. This transaction follows a period of no insider buys and three insider sells over the past year for Legend Biotech. The stock is cur", "url": "https://www.gurufocus.com/news/8943775/insider-sell-alert-patrick-casey-sells-6000-shares-of-legend-biotech-corp-legn", "source_name": "GuruFocus", "published_at": "2026-07-02T23:10:26", "published_display": "02 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN - Legend Biotech Corp ADR Earnings", "summary": "This article provides detailed financial data and performance metrics for Legend Biotech Corp ADR (LEGN). It includes key financial figures like market cap, income, sales, EPS, and various ratios, alongside stock performance over different periods. The data also covers ownership ", "url": "https://finviz.com/stock?t=LEGN&ta=1&p=w&ty=ea&b=2", "source_name": "Finviz", "published_at": "2026-07-02T16:39:24", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation Stock 12\u2011Month Price Target Cut to $55.21, Implies 85% Upside", "summary": "Legend Biotech Corporation's average 12-month stock price target has been lowered from $56.13 to $55.21 by 14 analysts, with forecasts ranging from $27 to $86 per share. This new target implies an 85% potential upside based on the July 1 closing price. Despite the target cut, the", "url": "https://www.tradingview.com/news/tradingview:6c4df68c2f6e1:0-legend-biotech-corporation-stock-12-month-price-target-cut-to-55-21-implies-85-upside/", "source_name": "TradingView", "published_at": "2026-07-02T16:10:26", "published_display": "02 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN - Legend Biotech Corp ADR Options", "summary": "This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The dat", "url": "https://finviz.com/stock?t=LEGN&p=d&ty=oc&b=2&ov=list_strike&s=2.5", "source_name": "Finviz", "published_at": "2026-07-02T15:40:38", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Legend Biotech Corp For: 30 June By Investing.com", "summary": "This article reports on the filing of Form 144 by Legend Biotech Corp for the period ending June 30. It provides financial market data including indices, commodities, bonds, and shares, along with a list of trending stocks and recent market movers. The article is a brief announce", "url": "https://ng.investing.com/news/stock-market-news/form-144-legend-biotech-corp-for-30-june-93CH-2580509", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T15:12:37", "published_display": "01 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Proposed ADS Sale (NASDAQ: LEGN)", "summary": "A Form 144 filing indicates a proposed sale of 3,000 American Depositary Shares (ADS) of Legend Biotech Corp (NASDAQ: LEGN) through Fidelity Brokerage Services LLC, valued at $88,800. The filing also details multiple past restricted stock vesting events totaling 3,000 ADS between", "url": "https://www.stocktitan.net/sec-filings/LEGN/144-legend-biotech-corp-sec-filing-0312b4d9df8b.html", "source_name": "Stock Titan", "published_at": "2026-06-30T14:38:55", "published_display": "30 Jun 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Legend Biotech Corp For: 29 June By Investing.com", "summary": "This article announces the filing of Form 4 for Legend Biotech Corp for June 29, as reported by Investing.com. It is a brief administrative notice primarily serving to disseminate this financial filing information. The content primarily consists of market data, trending stocks, a", "url": "https://za.investing.com/news/stock-market-news/form-4-legend-biotechcorp-for-29-june-93CH-4348922", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T03:10:12", "published_display": "30 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU tax", "summary": "Legend Biotech Corp's CEO, Ying Huang, reported the disposition of 5,566 ordinary shares on June 25, 2026, at a weighted average price of $14.78 per share. This transaction was non-discretionary and solely to cover withholding tax obligations upon the vesting of restricted share ", "url": "https://www.stocktitan.net/sec-filings/LEGN/form-4-legend-biotech-corp-insider-trading-activity-e40f3d8780e6.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:10:11", "published_display": "30 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "This article displays the \"Price to sales forward\" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It provides market data and financial information for the company, accessible through the TradingView platform. The page shows that the market was closed at the", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:39:15", "published_display": "27 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN)", "summary": "This page provides an overview of Legend Biotech Corporation's financial actuals and estimates, including reported data and analyst projections for income statements, balance sheets, cash flow, and valuation metrics. Users can compare actual results with average, high, and low es", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:07", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "This article displays the \"Enterprise value to EBIT forward\" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It indicates that the market was closed with no trades at the time of the data capture. The content is primarily a screenshot or data display from the", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:11:42", "published_display": "26 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEGN (NASDAQ) notice: Director/entity proposes sale of 2,783 ADS", "summary": "Legend Biotech Corp (LEGN) has filed a Form 144 proposing the sale of 2,783 American Depositary Shares (ADS) linked to a Restricted Stock Vesting event on June 22, 2026. The filing indicates a value of $79,016.88 and mentions execution through Fidelity Brokerage Services LLC. It ", "url": "https://www.stocktitan.net/sec-filings/LEGN/144-legend-biotech-corp-sec-filing-49647a84329d.html", "source_name": "Stock Titan", "published_at": "2026-06-26T19:11:42", "published_display": "26 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Did the Recent CARVYKTI Data Reveal About Its Potential", "summary": "Legend Biotech's CARVYKTI demonstrates strong efficacy and safety for multiple myeloma, with recent data supporting its use earlier in treatment. The company reported a significant surge in Q1 2026 sales, driven by global expansion and improved manufacturing efficiency, positioni", "url": "https://www.kavout.com/market-lens/what-did-the-recent-carvykti-data-reveal-about-its-potential", "source_name": "Kavout | AI", "published_at": "2026-06-26T09:10:41", "published_display": "26 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "This article from TradingView is a placeholder or an incomplete page focusing on the \"Enterprise value to revenue forward\" metric for Legend Biotech Corporation (NASDAQ:LEGN). It displays basic company information and navigation links for financial data, news, and community secti", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:41", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Legend Biotech Corporation \u2013 NASDAQ:LEGN", "summary": "The article provides financial data for Legend Biotech Corporation (NASDAQ: LEGN), specifically focusing on its Price to Book Forward metric. It displays the current value, change, and percentage change for this financial indicator. The content appears to be a snapshot from a fin", "url": "https://www.tradingview.com/symbols/NASDAQ-LEGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:09:48", "published_display": "25 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress", "summary": "UBS has raised its price target for Legend Biotech Corporation (LEGN) to $49, reiterating a Buy rating, due to promising early clinical findings for its LB5006 program. Additionally, the company reported positive initial clinical proof-of-concept results for LB2501, an investigat", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-corporation-legn-price-124048482.html", "source_name": "Market source", "published_at": "2026-06-25T13:09:47", "published_display": "25 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firm Advises Underwriters on Legend Biotech\u2019s Public Offering", "summary": "Wilson Sonsini Goodrich & Rosati advised the underwriters in Legend Biotech Corporation's recent underwritten public offering. Legend Biotech priced 7,700,000 American Depositary Shares at $29.35 per ADS, raising approximately $226 million before deductions. The underwriters also", "url": "https://www.wsgr.com/en/insights/firm-advises-underwriters-on-legend-biotechs-public-offering.html", "source_name": "Wilson Sonsini", "published_at": "2026-06-24T19:40:03", "published_display": "24 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Healthcare Stocks to Buy According to Wall Street Analysts", "summary": "This article identifies Legend Biotech Corporation (NASDAQ: LEGN) as one of the best healthcare stocks to buy according to Wall Street analysts, citing a price target increase by UBS and promising clinical trial results. The company's LB5006 program showed therapeutic activity an", "url": "https://www.insidermonkey.com/blog/5-best-healthcare-stocks-to-buy-according-to-wall-street-analysts-1788076/4", "source_name": "Insider Monkey", "published_at": "2026-06-24T18:40:03", "published_display": "24 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Apogee, 3 More Biotech Buyout Targets Wall Street Can\u2019t Stop Watching", "summary": "Following AbbVie's acquisition of Apogee Therapeutics, biotech M&A is seeing renewed interest. This article identifies three biotech companies as potential buyout targets for Wall Street: Revolution Medicines (RVMD), Structure Therapeutics (GPCR), and Legend Biotech (LEGN). Each ", "url": "https://247wallst.com/investing/2026/06/24/after-apogee-3-more-biotech-buyout-targets-wall-street-cant-stop-watching/", "source_name": "24/7 Wall St.", "published_at": "2026-06-24T11:55:03", "published_display": "24 Jun 2026 11:55", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Legend Biotech (LEGN) Is Down 17.3% After $226 Million Follow-On Offering Post LB2501 Data - And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Reports a Complete Response in Five of Six Patients at Its Highest Dose", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-legn-reports-complete-141426609.html", "source_name": "Insider Monkey", "published_at": "2026-06-22T14:14:26+00:00", "published_display": "22 Jun 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (NASDAQ: LEGN) prices $226M ADS sale to raise cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPYkdpOEZFVU1kdlN0NlFQZzRnV0NlT3FtNWFJSGhFck9XMmdFZzlxNUFWWHpfUVZLR0Z4TG5aZUVHcUlzejNRX1V2TlJTR2thSEVZUG5TZGdWOGxGeV82bnNWbDJZRE9BTnlSUzVRejBUZ3MtckxWLThqd0lRQlJoWld0UERSWnhNRUhhN0Q2MjFacFJ6dGhXUGFONDdaOWdpenYzWnBnUXMxYkxsM1ExZzZkSUdhZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Prices $226 Million ADS Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-prices-226-million-075949443.html", "source_name": "MT Newswires", "published_at": "2026-06-18T07:59:49+00:00", "published_display": "18 Jun 2026 07:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation Announces Pricing of Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-corporation-announces-pricing-012100514.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T01:21:00+00:00", "published_display": "18 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Starts $225 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-starts-225-million-210010263.html", "source_name": "MT Newswires", "published_at": "2026-06-17T21:00:10+00:00", "published_display": "17 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Corporation Announces Proposed Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/legend-biotech-corporation-announces-proposed-202900189.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T20:29:00+00:00", "published_display": "17 Jun 2026 20:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech seeks $225M in stock sale as markets stay open", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOMy1wdTl6VnVPYlJBdGJYejBGZlBfeFdDZEUxSEZKN2ZDYXpjUjFnQ1FjMkJ0V1F4UWp2NjlTbTVRcnBnUXFMeklmcEwxX3ZqbW9pdUZxSlZaWEQ0S292SmZ4VUlOOWo0TkhOV3MtZl9EMDVUaUYyV2VSMkhucTFjejk5ZGd4LWJxeGR1RGtLQmZONEo4NFBFbDlaVTN5djdadjNNZXlEcVV6SFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech sets $29.35 share price for $226M offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNQUZmNG5kZnltelU4dGtDeGdYT3BXenRiZTFva1dNREpaV3ZicjRpbFZRdWlfVkhVYWxRZ0lOTDNLajVHeVI0ckVHdEdSMzYycVJvQjBkemc3d3pHb0lyZmRDODRZQXlnX1JxQkRBb0NHRmZ2OFJ3NWstcEZfQy11bmFMYmItbzMxZFJEWE0yOFgzRFJ2em5jS3lfMlVIZGtXUUJKRVFkbFZTbWRNVmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech stock falls on $225M share offering plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONC1HM0tvaE85OU9rQThHejFpaUNZOXlraVY2SUNHakd0cnAzdDhidWdRLS15UjVXdm9wbGdaNnoyWHRSZVR0SXY2R3QxQnRhNFZ0b3J4eHk1M0dXY21MQUdZaGVQa3ctS3RNV1VDRVlLeUdPTVVBWGxEZU9zcDdKejc4ZHJoOHd0d2txUDZKMVNqV2Z1SjNwZVZDTzFnelJsNzFNbDlrR05aUlk5bloySGVvVFB6bUk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Reports Promising Data for LB2501 in B-cel", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQQU9wY1pXdl9yQl9hRlBRSW1MdmZzRGRJbVVQVEtLaVFRYjhRdTcyY3NUUTlUbkxrOFVZbUJ0dFhxRm02VTlIZUlUZTBHOFRXV2JVMEtpdjJwYno2NnZEZ3RqQU5BQzdRekVnU19YbHhzMURvTzQwUlE4SlctdTFzUkdScFA0T0NBbUxPYWdSRXoyODhndGY4elZ6MDVpWUx6ZVEyQ1JJeGFvTGNUNW1xWEk0Wmx6dmQyMVQ3MlpZZmdxZ3NmN1JPY182SzcyNkZqWWhCVE5LU1hab2xfS19nOVI0TUQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Single-dose lymphoma CAR-T from Legend Biotech hits 100% response at top dose", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQQkZXQ0V6NXM3OVZhcGFqNWY5bF9qcVF3R2NyZzZNUXA0Q3NIenV4UWZJR1JUejc0bXZJdjJUaEdsekhoM1ZNQnlBaU9aNExkdEZnZE5RaGRXUFhXVWtqZFNSeEtjUlBqVXVIOC1aQkNvNG5ERXJ2clcteDBWdW4tVnRtX2xCS2RWeEZLc0lkWWFyTjNXWERnN1E0RVFyUXlFUDltZGJwSEcwTXpwWEJFYU9FOHcyRlJlUFppbg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech Stock (LEGN) Opinions on In Vivo CAR-T Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQMUQ0TFdzVjdVTTBkR3VxNkFVTXp4VUJqampVRG1HQ05RemVfQ1RZTnktMGtqUzZmTFpickVvQksyNFFINWRUVl93LTdEd0JwcDJfWjlZX2E3V0phalJrWmQ4cmJ2X1ZkUGtkUTV2Z2tRZDd6OG54Qmh5aDk4VUJNeFpzek5FSERRTU42Q2JyUHA1Z3JXUDItcnpUZ0FGNlk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNbkNpTG5ua09CYm0zY2Z6OXYwSzRBVDdyZGM4SW1GUTFaWmFCbzlGRUZ3ZUcyeFpmRUlJM1VRMC04S2FQcEdjX2JQaV9JeDVHMXd5ZVhPX19VU1dyWHBDMHpCcEZQTUV0LWhCZXNSNXo5M29OOU02Sm13NE1YLWlWUEhwTk1qY2hISnVwc2V4d2NMc01acVFSUVFFVjZHdw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A China Tech Fund Opens a Biotech Position \u2014 Here's What That Actually Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNeVZBck5mY05IRzNMZFF4aEM0N0U2bkFZRExRT1gweG9YRWpyekNpaEtJS3VydVk1allOUzNWYmMtRE51SkFiTldVSnlXWEs2bVR2OWZHZVpKVmlYakZXTTJNUTNTV0hJNmxCOHppUTFJdXVkWjJocnoyaEh4QXhabVllS0hvWEVvb1lUQllXLVBodjRmbTE5d2s2SGpVUG45TmVmLTA5d3dySmdKYnJybFNqaWhGNFdwcVllRXRKV2w5X2FK?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Valuation After Strong Q1 2026 CARVYKTI Growth And Narrowing Losses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWC02OFFwV3pvVkl3V2thZ0tyVVEyRVhQSzJWdWpLSGtPc2VMVG5YWVFORjJWS0pyNkJlOTl4S1c2VDMxd0VwYXJ3LUR3aWNmSkMyaWZTX3p2VEtQYXhmMnRUSHZ4SFJTM0k3Yk5VWVYtZnZsck1pNC1rV1RjUk1BbDhfdkhKdTNwMGNVQ0Nxd19UdV83SDk1clRsYVdjczhCTHBZYkFQYUU?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legend Biotech (LEGN) Q1 Loss Persists And Tests Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Six cell therapy experts will advise Legend on its next medicines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdGkwZGRVVHJsLWxFdjBZejJ6R0pfMWdxSUdpRHpwMGc1MGtBTE1zdEg3aDVPZkFWLTVCS1ZCTTZLZDlGS2RUajBTWE5wVGRuU1lKcC1mNVQwZDNGSE5mcS12QTJmUHFqQ1BQTDFsX3hWMDktZGFrQlNwRGQ1QWZuVkFPY1dmcjdOcFFSUFg2cDJYOHg1Y0s5c2lSMlVTbDlFMlVKWDZnT0t0ZDhhUk9hTUhBX2x4TW9K?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Legend Biotech (LEGN) One of the Overlooked Growth Stocks to Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNN0ZpWFJvZEFSZkFVUEZFb0xod1lwTkpueURHNkpaTEdEWktpRmVsU1AyUmlWYmttd1piRURxZHhySkdsREpmV21mbF83Y0thUXJkUGFmV1lNdVk2dGR4NThOU1pDaUx5X2gtYk1wRmZxTDFxZHRtLVhDNWRwdlpqdnhMaWpGckdJUzBGR0pYeThPX3luSDRTb0J2d09FaHRG?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Legend Biotech (LEGN) Story Is Shifting As Analyst Expectations Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNdEVPYkNpZk5ITEhMSWk1OHVwVjNsdkdreEhlOHVSRmFLZ01ickFzSGJmcTBUc3REMGJ4VENmRkpWQTVBc1F2bWhOUXZjZTYtT3VWRVFqSTJzTjh4V0ptNjRZdFlRbzNybWJJTnZZdFdLQU1UeUhxdkRHX2F1TXJBRkkwVWMxRHNGNklPQjBvOTVsMHBqQjMxa0lUeW0xYXk1?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Legend Biotech (LEGN) Pricing Reflect Its Value After Recent Share Price Rebound?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 66, "sentiment_summary": {"positive": 13, "negative": 5, "neutral": 48, "score": 53, "total": 66, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 20.7, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 27.08, "latest_week": "2026-07-10", "one_week_move": -9.5, "four_week_move": -24.5, "twelve_week_move": 27.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.650232, "market_dynamics_buy_signal": false, "relative_strength": -15.769572, "fair_value_gap": -35.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.569, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.5% over one week, -24.5% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 6}, {"label": "GuruFocus", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Quiver Quantitative", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 8}, {"label": "Balance sheet", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-9.5% over one week, -24.5% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed"}], "updated_at": "2026-07-16T16:23:30.753330+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}